KB408

AXP000195.1 · Viral vector gene therapy

Platform
HSV-1 (replication-defective)
Targets
SERPINA1
Originator
Krystal Biotech
Sponsor
Krystal Biotech

Names

NameTypeSource
KB408preferred name, codecurator, press
SERPENTINE-1 ambiguoussynonympress

Virus

Role
In vivo gene transfer
Family
Herpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
non replicating
Modifications
replication-defective HSV-1 backbone; two copies of SERPINA1
Transgenes
SERPINA1
Route
inhaled
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06049082A Study of KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyRecruitingPhase 12024-02-152025-1215Alpha 1-Antitrypsin Deficiency

Recent changes

No changes recorded in its trials yet.

Notes

Nebulised (inhaled) replication-defective HSV-1 vector delivering two copies of SERPINA1 (normal human alpha-1 antitrypsin), for alpha-1 antitrypsin deficiency (PI*ZZ); phase 1 SERPENTINE-1, NCT06049082, first patient dosed February 2024. Route left empty because 'inhaled' is not in the route vocabulary.

How to cite

KB408 (AXP000195.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000195.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.